REFERENCES
1. Barnholtz-Sloan S, Sloan J, Davis A, Vigneau FD, Lai F, et al. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 2004;22:2865-72.
2. Miller AJ, Mihm MC. Melanoma. N Engl J Med 2006;355:51-65.
3. Salvati M, Cervoni L, Caruso R, Gagliardi FM. Solitary cerebral metastasis from melanoma: value of the 'en bloc' resection. Clin Neurol Neurosurg 1996;98:12-4.
4. Hanson PW, Elaimy AL, Lamoreaux WT, Demakas JJ, Fairbanks RK, et al. A concise review of the efficacy of stereotactic radiosurgery in the management of melanoma and renal cell carcinoma brain metastases. World J Surg Oncol 2012;10:176.
5. Queirolo P, Spagnolo F, Picasso V, Spano L, Tanda E, et al. Combined vemurafenib and fotemustine in patients with BRAFV600 melanoma progressing on vemurafenib. Oncotarget 2016;9:12408-17.
6. Kienast Y, von Baumgarten L, Fuhrmann M, Klinkert WE, Goldbrunner R, et al. Real-time imaging reveals the single steps of brain metastasis formation. Nat Med 2010;16:116-22.
7. Preusser M, Capper D, Ilhan-Mutlu A, Berghoff AS, Birner P, et al. Brain metastases: pathobiology and emerging targeted therapies. Acta Neuropathol 2012;123:205-22.
8. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
9. Margolin K. The promise of molecularly targeted and immunotherapy for advanced melanoma. Curr Treat Options Oncol 2016;17:48.
10. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
11. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012;366:707-14.
12. Cagney DN, Alexander BM, Hodi FS, Buchbinder EI, Ott PA, et al. Rapid progression of intracranial melanoma metastases controlled with combined BRAF/MEK inhibition after discontinuation of therapy: a clinical challenge. J Neurooncol 2016;129:389-93.
13. Weidle UH, Birzele F, Kollmorgen G, Rüger R. Dissection of the process of brain metastasis reveals targets and mechanisms for molecular-based intervention. Cancer Genomics Proteomics 2016;13:245-58.
14. Dawood S, Austin L, Cristofanilli M. Cancer stem cells: implications for cancer therapy. Oncology (Williston Park) 2014;28:1101-7.
15. Shipitsin M, Polyak K. The cancer stem cell hypothesis: in search of definitions, markers, and relevance. Lab Invest 2008;88:459-63.
16. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Nat Acad Sci 2003;100:3983-8.
17. Bradshaw A, Wickremesekera A, Brasch HD, Chibnall AM, Davis PF, et al. Cancer stem cells in glioblastoma multiforme. Front Surg 2016;3:48.
18. Ram R, Brasch HD, Dunne JC, Davis PF, Tan ST, et al. The identification of three cancer stem cell subpopulations within moderately differentiated lip squamous cell carcinoma. Front Surg 2017;4:12.
19. Baillie R, Itinteang T, Yu HH, Brasch HD, Davis PF, et al. Cancer stem cells in moderately differentiated oral tongue squamous cell carcinoma. J Clin Pathol 2016;69:742-4.
20. Yu HH, Featherston T, Tan ST, Chibnall AM, et al. Characterization of cancer stem cells in moderately differentiated buccal mucosal squamous cell carcinoma. Front Surg 2016;3:46.
21. Wickremesekera AC, Brasch HD, Lee VM, Davis PF, Woon K, et al. Putative cancer stem cell subpopulations in metastatic melanoma to the brain. J Clin Neurosci 2019;60:112-6.
22. Deshayes F, Nahmias C. Angiotensin receptors: a new role in cancer? Trends Endocrinol Metab 2005;16:293-9.
23. Farag E, Sessler DI, Ebrahim Z, Kurz A, Morgan J, et al. The renin angiotensin system and the brain: New developments. J Clin Neurosci 2017;46:1-8.
24. Juillerat-Jeanneret L, Celerier J, Chapuis Bernasconi C, Nguyen G, Wostl W, et al. Renin and angiotensinogen expression and functions in growth and apoptosis of human glioblastoma. Br J Cancer 2004;90:1059-68.
25. Arundhathi A, Chuang WH, Chen JK, Wang SE, Shyr YM, et al. Prorenin receptor acts as a potential molecular target for pancreatic ductal adenocarcinoma diagnosis. Oncotarget 2016;7:55437-48.
26. Bradshaw AR, Wickremesekera AC, Brasch HD, Chibnall AM, Davis PF, et al. Glioblastoma multiforme cancer stem cells express components of the renin-angiotensin system. Front Surg 2016;3:51.
27. Featherston T, Yu HH, Dunne JC, Chibnall AM, Brasch HD, et al. Cancer stem cells in moderately differentiated buccal mucosal squamous cell carcinoma express components of the renin-angiotensin system. Front Surg 2016;3:52.
28. Ram RS, Brasch HD, Dunne JC, Davis PF, Tan ST, et al. Cancer stem cells in moderately differentiated lip squamous cell carcinoma express components of the renin–angiotensin system. Front Surg 2017;4:30.
29. Baillie R, Itinteang T, Yu HH, Brasch HD, Davis PF, et al. Cancer stem cells in moderately differentiated oral tongue squamous cell carcinoma express components of the renin–angiotensin system. J Clin Pathol 2016;69:942-5.
30. Tan EM, Chudakova DA, Davis PF, Brasch HD, Itinteang T, et al. Characterisation of subpopulations of myeloid cells in infantile haemangioma. J Clin Pathol 2015;68:571-4.
31. Steckelings UM, Wollschläger T, Peters J, Henz BM, Hermes B, et al. Human skin: source of and target organ for angiotensin II. Exp Dermatol 2004;13:148-54.
32. Itinteang T, Marsh R, Davis PF, Tan ST. Angiotensin II causes cellular proliferation in infantile haemangioma via angiotensin II receptor 2 activation. J Clin Pathol 2015;68:346-50.
33. Koh SL, Ager EI, Costa PLN, Malcontenti-Wilson C, Muralidharan V, et al. Blockade of the renin-angiotensin system inhibits growth of colorectal cancer liver metastases in the regenerating liver. Clin Exp Metastas 2014;31:395-405.
